Delayed Clinical Response in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept

Author(s):
Otten, M.H.; Prince, F.H.M.; Twilt, M.; Rossum, M.A.J. van; Armbrust, W.; Hoppenreijs, E.P.A.H.; Kamphuis, S.; Koopman-Keemink, Y.; Wulffraat, N.M.; Gorter, S.L.; Cate, R. ten; Suijlekom-Smit, L.W.A. van
Published
2010
Publication type
Article / Letter to editor

Abstract

Objective. To evaluate response in patients with juvenile idiopathic arthritis (JIA) who failed to meet response criteria after 3 months of etanercept treatment. Methods. This was a prospective ongoing Multicenter observational study of all Dutch patients with JIA using etanercept. Response according to American College of Rheumatology Pediatric 30 criteria was assessed at study start and at 3 and 15 months. Results. In total we studied 179 patients of median age 5.8 years at disease onset; 70% were female. Thirty-four patients did not respond after 3 months, of which 20 continued etanercept and 11 achieved response thereafter. Conclusion. The delayed clinically relevant response in a substantial proportion of patients who initially did not respond justifies the consideration of continuing therapy to at least 6 months. (First Release Jan 15 2010; J Rheumatol 20 10;37:665-7 doi: 10.3899/jrheum.090550)

JUVENILE IDIOPATHIC ARTHRITIS ANTIRHEUMATIC AGENTS TUMOR NECROSIS FACTOR-alpha DRUG ADMINISTRATION SCHEDULE TREATMENT OUTCOME ARTHRITIS rheumatoid-arthritis efficacy children therapy safety
Date issued
2010-03-31
Language
English
Is part of
Journal of Rheumatology (2010), Vol. 37, no. 3, p. 665-667
hdl
1887/110214
doi
10.3899/jrheum.090550